Download SAMPLE CME STATEMENTS—EACH OF THESE STATEMENTS

Program Title: The Emerging Role of SGLT Inhibitors in Individualized Treatment of T2DM
Activity Faculty
George L. Bakris, MD
Professor of Medicine
Director, ASH Comprehensive Hypertension Center
The University of Chicago
Chicago, Illinois
45 Minutes: The Emerging Role of SGLT Inhibitors in Individualized Treatment of T2DM
15 minutes: Questions and Answers
Content Faculty
John E. Gerich, MD (Chair)
University of Rochester School of Medicine
George L. Bakris, MD
The University of Chicago
Robert R. Henry, MD
University of California, San Diego
Veterans Affairs Healthcare System
Lawrence A. Leiter, MD, FRCP(C), FACP
University of Toronto
Vivian A. Fonseca, MD, FRCP
Tulane University School of Medicine
Sponsored by
Target Audience
This activity is intended for primary care physicians and other health care professionals who manage patients
with type 2 diabetes.
Educational Activity Learning Objectives
Upon completion of this course, the participants should be able to:
 Define individual T2DM and cardiovascular disease goals
 Formulate a patient management strategy that targets the “ABCs”: A1C, Blood Pressure, and Cholesterol
 Explain the rationale for targeting renal glucose transport, and interpret related clinical data and the
potential role
 Distinguish the unique differences between new SGLT2 inhibitors and discuss the clinical implications of
these differences on appropriate patient selection
Statement of Need
This activity is designed to improve knowledge, competency, and practice improvements in the diagnosis,
management, and treatment of patients with type 2 diabetes mellitus (T2DM).
Disclosures
It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its
sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this
activity will disclose to the participants any significant financial interest or other relationship with
manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in
this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other
relationship from participating in the activity, but rather to provide participants with information on which they
can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest
prior to the release of this activity.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control
content have no relevant financial relationships to disclose.
Faculty DisclosuresContent Creators
The following faculty have indicated they have relationships with industry to disclose relative to the content of
this CME activity:
 John E. Gerich, MD, has served as a consultant for and/or received honoraria from Janssen, Boehringer
Ingelheim, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Sanofi, and Merck
 George L. Bakris, MD, has received grant and research support from Takeda and has served as a
consultant for Janssen, Medtronic, Relypsa, Takeda, Daiichi-Sankyo, Boehringer Ingelheim, and BristolMyers Squibb
 Vivian A. Fonseca, MD, FRCP, has received research support from Novo-Nordisk, Sanofi-Aventis, Eli Lilly,
Abbott, Pan American Laboratories, Reata, and Endo Barrier and has served as a consultant and speaker
for GlaxoSmithKline, Takeda, Novo-Nordisk, Sanofi Aventis, Eli Lilly, Daiichi-Sankyo, Pamlab, AstraZeneca,
Abbott, Bristol-Myers Squibb, and Boehringer Ingelheim
 Robert R. Henry, MD, has received grant and research support from AstraZeneca, Bristol-Myers Squibb,
Eli Lilly, Sanofi-Aventis, and has served as a consultant or on an advisory board for Alere, Amgen,
Boehringer Ingelheim, Bristol-Myers Squibb, ClinMet, Daiichi Sankyo, Eisai, Elcelyx, Gilead, Hitachi,
Intarcia, Isis, Johnson & Johnson/Janssen, Eli Lilly, Merck, Novo Nordisk, Roche/Genentech, Sanofi
Aventis, and Vivus, Inc
 Lawrence Leiter, MD, FRCP(C), FACP, has received grants, research support, and has served as
consultants for Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly,
GlaxoSmithKline, Merck, Novo Nordisk, Roche, Sanofi, Servier, and Takeda. Dr. Leiter has received
honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Novo
Nordisk, Sanofi, and Takeda
Faculty DisclosuresFaculty Activity
The following faculty has indicated he has relationships with industry to disclose relative to the content of this
CME activity:
 George L. Bakris, MD, has received grant and research support from Takeda and has served as a
consultant for Janssen, Medtronic, Relypsa, Takeda, Daiichi-Sankyo, Boehringer Ingelheim, and BristolMyers Squibb
Unapproved Use Disclosure
The France Foundation requires CME faculty (speakers) to disclose to the attendees when products or
procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved);
and any limitations on the information that is presented, such as data that are preliminary or that represent
ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information
about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This
information is intended solely for continuing medical education and is not intended to promote off-label use of
these medications. If you have questions, contact the medical affairs department of the manufacturer for the
most recent prescribing information.
Commercial Support Acknowledgment
This activity is supported by an educational grant from Bristol-Myers Squibb and AstraZeneca.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by
faculty who have been selected because of recognized expertise in their field. Participants have the professional
responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical
judgment and accepted standards of care. The France Foundation, Bristol-Myers Squibb, and AstraZeneca
assume no liability for the information herein.